117 related articles for article (PubMed ID: 33073226)
1. In-depth characterization of the biomarkers based on tumor-infiltrated immune cells reveals implications for diagnosis and prognosis in hepatocellular carcinoma.
Chen W; Bi K; Zhang X; Jiang J; Diao H
J Transl Autoimmun; 2020; 3():100067. PubMed ID: 33073226
[TBL] [Abstract][Full Text] [Related]
2. Significance of tumor-infiltrating immunocytes for predicting prognosis of hepatitis B virus-related hepatocellular carcinoma.
Chen QF; Li W; Wu PH; Shen LJ; Huang ZL
World J Gastroenterol; 2019 Sep; 25(35):5266-5282. PubMed ID: 31558872
[TBL] [Abstract][Full Text] [Related]
3. Construction and validation of a joint diagnosis model based on random forest and artificial intelligence network for hepatitis B-related hepatocellular carcinoma.
Jiang X; Hu J; Xie S
Transl Cancer Res; 2024 Feb; 13(2):1068-1082. PubMed ID: 38482416
[TBL] [Abstract][Full Text] [Related]
4. Identification and Validation of Tumor Stromal Immunotype in Patients With Hepatocellular Carcinoma.
Li W; Xu L; Han J; Yuan K; Wu H
Front Oncol; 2019; 9():664. PubMed ID: 31448222
[No Abstract] [Full Text] [Related]
5. Identification and Validation of Immune-Related Gene Prognostic Signature for Hepatocellular Carcinoma.
Chen W; Ou M; Tang D; Dai Y; Du W
J Immunol Res; 2020; 2020():5494858. PubMed ID: 32211443
[TBL] [Abstract][Full Text] [Related]
6. Identification of Energy Metabolism Genes for the Prediction of Survival in Hepatocellular Carcinoma.
Chen Q; Li F; Gao Y; Xu G; Liang L; Xu J
Front Oncol; 2020; 10():1210. PubMed ID: 32903581
[TBL] [Abstract][Full Text] [Related]
7. Mining Prognostic Biomarkers of Hepatocellular Carcinoma Based on Immune-Associated Genes.
Chen W; Tang D; Ou M; Dai Y
DNA Cell Biol; 2020 Apr; 39(4):499-512. PubMed ID: 32069130
[TBL] [Abstract][Full Text] [Related]
8. Construction and Validation of Novel Diagnostic and Prognostic DNA Methylation Signatures for Hepatocellular Carcinoma.
Li R; Shui L; Jia J; Wu C
Front Genet; 2020; 11():906. PubMed ID: 32922438
[TBL] [Abstract][Full Text] [Related]
9. High RPS3A expression correlates with low tumor immune cell infiltration and unfavorable prognosis in hepatocellular carcinoma patients.
Zhou C; Weng J; Liu C; Zhou Q; Chen W; Hsu JL; Sun J; Atyah M; Xu Y; Shi Y; Shen Y; Dong Q; Hung MC; Ren N
Am J Cancer Res; 2020; 10(9):2768-2784. PubMed ID: 33042616
[TBL] [Abstract][Full Text] [Related]
10. Development and validation of a TP53-associated immune prognostic model for hepatocellular carcinoma.
Long J; Wang A; Bai Y; Lin J; Yang X; Wang D; Yang X; Jiang Y; Zhao H
EBioMedicine; 2019 Apr; 42():363-374. PubMed ID: 30885723
[TBL] [Abstract][Full Text] [Related]
11. DNA methylation-driven genes for constructing diagnostic, prognostic, and recurrence models for hepatocellular carcinoma.
Long J; Chen P; Lin J; Bai Y; Yang X; Bian J; Lin Y; Wang D; Yang X; Zheng Y; Sang X; Zhao H
Theranostics; 2019; 9(24):7251-7267. PubMed ID: 31695766
[TBL] [Abstract][Full Text] [Related]
12. A novel prognostic biomarker SPC24 up-regulated in hepatocellular carcinoma.
Zhu P; Jin J; Liao Y; Li J; Yu XZ; Liao W; He S
Oncotarget; 2015 Dec; 6(38):41383-97. PubMed ID: 26515591
[TBL] [Abstract][Full Text] [Related]
13. Construction of a risk score prognosis model based on hepatocellular carcinoma microenvironment.
Zhang FP; Huang YP; Luo WX; Deng WY; Liu CQ; Xu LB; Liu C
World J Gastroenterol; 2020 Jan; 26(2):134-153. PubMed ID: 31969776
[TBL] [Abstract][Full Text] [Related]
14. PD1
Ma J; Zheng B; Goswami S; Meng L; Zhang D; Cao C; Li T; Zhu F; Ma L; Zhang Z; Zhang S; Duan M; Chen Q; Gao Q; Zhang X
J Immunother Cancer; 2019 Nov; 7(1):331. PubMed ID: 31783783
[TBL] [Abstract][Full Text] [Related]
15. Overexpression of PARPBP Correlates with Tumor Progression and Poor Prognosis in Hepatocellular Carcinoma.
Yu B; Ding Y; Liao X; Wang C; Wang B; Chen X
Dig Dis Sci; 2019 Oct; 64(10):2878-2892. PubMed ID: 30949905
[TBL] [Abstract][Full Text] [Related]
16. Tissue-infiltrating lymphocytes signature predicts survival in patients with early/intermediate stage hepatocellular carcinoma.
Tian MX; Liu WR; Wang H; Zhou YF; Jin L; Jiang XF; Tao CY; Tang Z; Zhou PY; Fang Y; Qu WF; Ding ZB; Peng YF; Dai Z; Qiu SJ; Zhou J; Lau WY; Fan J; Shi YH
BMC Med; 2019 Jun; 17(1):106. PubMed ID: 31164128
[TBL] [Abstract][Full Text] [Related]
17. Identification and Validation of a Prognostic lncRNA Signature for Hepatocellular Carcinoma.
Li W; Chen QF; Huang T; Wu P; Shen L; Huang ZL
Front Oncol; 2020; 10():780. PubMed ID: 32587825
[No Abstract] [Full Text] [Related]
18. [Differential analysis of gene expression profiles in hepatocellular carcinoma patients with high and low levels of alpha-fetoprotein].
Wang XJ; Shen RF; Wang X; Wang YR; Xiao T
Zhonghua Zhong Liu Za Zhi; 2020 May; 42(5):396-402. PubMed ID: 32482029
[No Abstract] [Full Text] [Related]
19. Regulatory T cell and activated natural killer cell infiltration in hepatocellular carcinoma: immune cell profiling using the CIBERSORT.
Wang L; Yang Z; Cao Y
Ann Transl Med; 2020 Nov; 8(22):1483. PubMed ID: 33313228
[TBL] [Abstract][Full Text] [Related]
20. A Novel Ten-Gene Signature Predicting Prognosis in Hepatocellular Carcinoma.
Zhou T; Cai Z; Ma N; Xie W; Gao C; Huang M; Bai Y; Ni Y; Tang Y
Front Cell Dev Biol; 2020; 8():629. PubMed ID: 32760725
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
